天然产物研究与开发 ›› 2016, Vol. 28 ›› Issue (5): 680-684.doi: 10.16333/j.1001-6880.2016.5.007

• 研究论文 • 上一篇    下一篇

灯盏甲素在正常和脑缺血再灌注损伤大鼠体内的药代动力学研究

胡杰1,3,侯佳1,李月婷1,3,王爱民1,2,黄勇1,3*   

  1. 1 贵州医科大学贵州省药物制剂重点实验室;2 贵州医科大学民族药与中药开发应用教育部工程研究中心;3 贵州医科大学药学院,贵阳 550004
  • 出版日期:2016-05-28 发布日期:2016-09-06

Pharmacokinetics of Apigenin-7-O-glucronide in Normal and Middle Cerebral Artery Occlusion Rats

HU Jie1,3,HOU Jia1,LI Yue-ting1,3,WANG Ai-min1,2,HUANG Yong1,3*   

  1. 1 Guizhou Provincial Key Laboratory of Pharmaceutics,School of Pharmacy;2 Engineering Research Center for the Development and Application of Ethnic Medicine and TCM(Ministry of Education),Guizhou Medical University;3 School of Pharmacy,Guizhou Medical University,Guiyang 550004,China
  • Online:2016-05-28 Published:2016-09-06

摘要: 建立准确、灵敏的超高效液相色谱-串联质谱(UPLC-MS)法,研究灯盏甲素在正常和脑缺血再灌注损伤(MCAO)大鼠体内的药代动力学。采用改良Zea longa方法制作MCAO模型,正常和模型大鼠灌服灯盏细辛提取物后,UPLC-MS法测定灯盏甲素的血药浓度,通过DAS2.0软件拟合出药动学参数,SPSS11.5统计学软件对结果进行统计分析,比较灯盏甲素在正常和MCAO大鼠体内的药代动力学差异。与正常大鼠的药动学特征相比,灯盏甲素在MCAO大鼠血浆中的药时曲线下面积(AUC)、达峰浓度(Cmax)均明显增大,清除率(ClZ/F)、表观分布容积(VZ/F)和平均滞留时间(MRT)减小,其血药浓度-时间曲线存在明显的双峰。表明灯盏甲素在MCAO大鼠体内较正常大鼠体内生物利用度显著提高,反应了该药用于临床治疗脑缺血损伤疾病的合理性。造成这种差异吸收的原因可能是脑缺血再灌注损伤机体的膜通透性增强使药物跨膜转运加快,也可能是毛细血管通透性增强使通过细胞旁路通道的药物转运加快。

关键词: 超高效液相色谱-串联质谱, 灯盏细辛提取物, 灯盏甲素, 脑缺血再灌注损伤模型, 药代动力学

Abstract: To develop an accurate and sensitive ultra-performance liquid chromatography-tandem mass spectrometry(UPLC-MS) method for determination of apigenin-7-O-glucronide in rat plasma and study the pharmacokinetics of apigenin-7-O-glucronide in normal rat and middle cerebral artery occlusion(MCAO) rat.MCAO model was established by meliorative Zea longa method.Normal group and model group were given orally with Erigeron breviscapus extract.The concentrations of apigenin-7-O-glucronide in rat plasma of normal group and model group were compared after oral administration of the same dose of E.breviscapus extract.Compared with normal group,the values of AUC and Cmax increased and the values of  ClZ/F, VZ/F and MRT decreased in model group.The results indicated that bioavailability of model group increased remarkably,which reflected the rationality of apigenin-7-O-glucronide in the clinical treatment of cerebral ischemia diseases.

Key words: UPLC-MS, Erigeron breviscapus;apigenin-7-O-glucronide;middle cerebral artery occlusion model;pharmacokinetics

中图分类号: 

R969.1